4/A: Entrada Therapeutics Director Amends Filing to Disclose Additional Share Purchase

Entrada Therapeutics Director Peter S. Kim filed an amended Form 4 to correct an omission, revealing an additional purchase of 25,000 shares of common stock on May 13, 2024, alongside a previously reported purchase on May 14, 2024.

Summary

• Peter S. Kim, a Director of Entrada Therapeutics, Inc. (TRDA), filed a Form 4/A to amend a previously filed Form 4.
• The amendment corrects an inadvertent omission of a purchase of 25,000 shares of common stock on May 13, 2024.
• These 25,000 shares were purchased at a weighted average price of $14.6804, with prices ranging from $14.63 to $14.76.
• The original Form 4, filed on May 16, 2024, had reported only the purchase of 25,000 shares on May 14, 2024.
• The May 14, 2024, purchase was at a weighted average price of $14.5869, with prices ranging from $14.465 to $14.73.
• Following both transactions, Peter S. Kim's direct beneficial ownership of Entrada Therapeutics common stock increased to 117,412 shares.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the significant insider buying by a director, indicating confidence in the company. The amendment itself is a neutral compliance action.

Positives

• The director's purchase of an additional 25,000 shares, totaling 50,000 shares across two days, indicates increased confidence from an insider in the company's future prospects.
• The increased beneficial ownership by a director aligns management's interests more closely with those of shareholders.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategy.

Management Comments

• The reporting person filed this Form 4/A to correct an inadvertent omission of a purchase of 25,000 shares of common stock on May 13, 2024, and to correct certain totals.

Industry Context

This filing represents an insider transaction, which is a common occurrence across all industries. While it doesn't directly reflect broader industry trends, insider buying in the biotechnology sector can sometimes signal optimism about a company's pipeline or market position.

Stakeholder Impact

• Shareholders: The insider buying by a director may be viewed positively, potentially increasing investor confidence and demand for the stock.

Key Dates

Recommendation

Keywords

Entrada Therapeutics, TRDA, Insider Trading, Form 4/A, Share Purchase, Director, Beneficial Ownership, SEC Filing, Biotechnology